Maraviroc
94 interactions 1 explained in plain English 343 cited referencesMaraviroc is used along with other medications to treat a certain type of human immunodeficiency virus (HIV) infection in adults and children who weigh at least 4.4 lb (2 kg). Maraviroc is in a class of medications called HIV entry and fusion inhibitors. It works by decreasing the amount of HIV in the blood. Although m… Read the full Maraviroc drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Maraviroc Venetoclax Venclexta Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Maraviroc Vimseltinib Romvimza Increased risk of P-gp substrate exposure Details Maraviroc Voriconazole Vfend Increased maraviroc exposure DetailsModerate
Maraviroc Trospium / Xanomeline Cobenfy Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Maraviroc Amprenavir Increased maraviroc concentrations Details Maraviroc Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Maraviroc Kratom Increased CYP3A substrate exposure Details Maraviroc Levacetylleucine Aqneursa Increased P-gp inhibitor exposure and an increased risk of P-gp substrate-related adverse reactions Details Maraviroc Lomitapide Increased P-gp substrate exposure Details Maraviroc Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Maraviroc Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Maraviroc Sparsentan Filspari Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Maraviroc Xanomeline Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Maraviroc Yellow Fever Vaccine Stamaril Increased risk of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in HIV-infected patients DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist